NCT00562003 Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients Status COMPLETED Phase PHASE1
NCT00526617 A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients Status COMPLETED Phase PHASE1
NCT00520013 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Status COMPLETED Phase PHASE2
NCT00489359 Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT00479817 Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer Status COMPLETED Phase PHASE2
NCT00466986 Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer Status COMPLETED Phase PHASE2
NCT00436215 Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer Status COMPLETED Phase PHASE2
NCT00428610 A Study of Chemotherapy Treatment for Patients With Ovarian Cancer Status COMPLETED Phase PHASE2
NCT00418093 Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma Status TERMINATED Phase PHASE2
NCT00314678 Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer Status COMPLETED Phase PHASE2
NCT00226915 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Status COMPLETED Phase PHASE3
NCT00157560 Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma Status COMPLETED Phase PHASE2
NCT00109096 Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy Status COMPLETED Phase PHASE2
NCT00059618 PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Status COMPLETED Phase PHASE1